<DOC>
	<DOC>NCT01752985</DOC>
	<brief_summary>The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease</brief_summary>
	<brief_title>Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Clinical diagnosis of type 2 diabetes mellitus with macroalbuminuria (UACR between 200 and 3500 mg/g) Background angiotensin converting enzyme inhibitor (ACEI) or angiotensinreceptor blocker (ARB) therapy Clinical diagnosis of type 1 diabetes Unstable cardiovascular, metabolic, or other chronic disease status Estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73 m2 High risk of infection or immune compromise Clinically significant ECG conduction abnormalities Drugs with significant potential to affect BMS813160 exposure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>